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Toward Improving Patients’ Experiences of Acute
Toxicity From Breast Radiotherapy: Insights From
the Analysis of Patient-Reported Outcomes in
a Large Multicenter Cohort
Reshma Jagsi, MD, DPhil1; Kent A. Grifﬁth, MPH, MS1; Frank Vicini, MD2; Thomas Boike, MD, MMM2; Jacob Burmeister, PhD3;
Michael M. Dominello, DO3; Inga Grills, MD4; James A. Hayman, MD1; Jean M. Moran, PhD1; Peter Paximadis, MD5;
Jeffrey D. Radawski, MD6; Eleanor M. Walker, PhD7; and Lori J. Pierce, MD1 on behalf of the Michigan Radiation Oncology Quality
Consortium

abstract

PURPOSE Understanding acute toxicities after whole-breast radiotherapy is important to inform patients, guide
treatment decisions, and target supportive care. We evaluated patient-reported outcomes prospectively collected from a cohort of patients with breast cancer.
METHODS We describe the maximal toxicity reported by 8,711 patients treated between 2012 and 2019 at 27
practices. Multivariable models identiﬁed characteristics associated with (1) breast pain, (2) bother from itching,
stinging/burning, swelling, or hurting of the treated breast, and (3) fatigue within 7 days of completing
whole-breast radiotherapy.

RESULTS Moderate or severe breast pain was reported by 3,233 (37.1%): 1,282 (28.9%) of those receiving
hypofractionation and 1,951 (45.7%) of those receiving conventional fractionation. Frequent bother from at least
one breast symptom was reported by 4,424 (50.8%): 1,833 (41.3%) after hypofractionation and 2,591 (60.7%)
after conventional fractionation. Severe fatigue was reported by 2,008 (23.1%): 843 (19.0%) after hypofractionation and 1,165 (27.3%) after conventional fractionation. Among patients receiving hypofractionated
radiotherapy, younger age (P , .001), higher body mass index (BMI; P , .001), Black (P , .001) or other race
(P 5 .002), smoking status (P , .001), larger breast volume (P 5 .002), lack of chemotherapy receipt
(P 5 .004), receipt of boost treatment (P , .001), and treatment at a nonteaching center predicted breast pain.
Among patients receiving conventionally fractionated radiotherapy, younger age (P , .001), higher BMI
(P 5 .003), Black (P , .001) or other race (P 5 .002), diabetes (P 5 .001), smoking status (P , .001), and
larger breast volume (P , .001) predicted breast pain.
CONCLUSION In this large observational data set, substantial differences existed according to radiotherapy dose
fractionation. Race-related differences in pain existed despite controlling for multiple other factors; additional
research is needed to understand what drives these differences to target potentially modiﬁable factors. Intensifying supportive care may be appropriate for subgroups identiﬁed as being vulnerable to greater toxicity.
J Clin Oncol 38:4019-4029. © 2020 by American Society of Clinical Oncology
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INTRODUCTION
Meta-analysis of randomized trials has demonstrated
convincingly that radiation therapy provides substantial beneﬁts in local control and modest improvements in survival for many patients with earlystage breast cancer.1 Radiotherapy is also known
to cause both acute and late toxicity. Acute effects
include fatigue and radiation dermatitis, and inﬂammatory symptoms may bother patients. Prior
work2 has demonstrated that acute toxicity appears
less frequently with the moderately hypofractionated
schedules that are now guideline supported for most
node-negative patients undergoing breast-conserving

surgery.3 Nevertheless, nearly one half of all patients
may experience grade 2 or greater acute toxicity even
with these newer approaches.4
Patients often have fears about radiation-related
toxicity.5-8 In one recent survey, 19% of patients with
breast cancer felt they lacked sufﬁcient information about the adverse effects to expect, and 32%
indicated experiencing adverse effects that they
wished they had known more about.9 Although some
of this might be remediated by greater attention to
physician-patient communication, the ability to fully
inform patients is limited by gaps in the existing literature. Currently, there is a paucity of information that
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CONTEXT
Key Objective
To understand patient experiences with acute toxicity after whole-breast radiotherapy in a large multicenter cohort of
patients with breast cancer treated in the United States between 2012 and 2019.
Knowledge Generated
We found that patients receiving moderately hypofractionated whole-breast radiotherapy reported considerably less acute
toxicity. Race-related differences in pain experiences existed despite controlling for multiple other factors, with worse
pain among women who were Black or whose race was deﬁned as “other” (not White, Asian, or Black).
Relevance
These ﬁndings are useful to inform patients, guide treatment decisions, and target supportive care.

characterizes the experiences of radiation toxicity from the
perspective of the patients themselves.10 Moreover, beyond
the impact of fractionation, little is known about whether
certain subgroups of patients (on the basis of treatment
characteristics or underlying factors) may have higher risks
of toxicity after whole-breast irradiation.
Because an understanding of acute patient-reported toxicities after breast radiotherapy would be valuable to inform
patients, guide treatment decisions, and target supportive
care interventions, we evaluated patient-reported outcomes in a statewide multicenter consortium, including
prospectively collected data from a large cohort of women
with breast cancer who received whole-breast radiotherapy
after breast-conserving surgery.

METHODS
Data Collection and Sample
As part of a collaborative quality improvement initiative,
the Michigan Radiation Oncology Quality Consortium
(MROQC) prospectively collects clinical, dosimetric, and
patient-reported outcomes data from women treated for
breast cancer at 27 practices, together with information
about facilities and providers.11 Eligible patients during the
study period were those being treated with adjuvant wholebreast radiotherapy for nonmetastatic, unilateral breast
cancer at an MROQC-participating institution.
This effort is institutional review board approved as a collaborative quality initiative; clinical information on all eligible
patients is entered into the database, but patient participation in surveys is voluntary (with written consent documentation waived). Practices are provided with staff
support, funded by Blue Cross Blue Shield of Michigan, to
gather data on all patients treated with lumpectomy and
unilateral whole-breast radiotherapy, regardless of insurer.
Those practices that meet the quality benchmarks are
provided with a “gold card” certiﬁcation that eliminates the
need for prior authorization for treatment if the patient is
insured by Blue Cross Blue Shield of Michigan.

A total of 12,577 patients were treated with lumpectomy
and whole-breast radiotherapy at MROQC sites and had
data entered into the MROQC database between January 1,
2012, and September 30, 2019. We describe here the
maximal toxicity reported by the 8,711 patients who provided survey responses within 7 days before or after the end
of treatment and for whom we had sufﬁcient data to determine dose fractionation and treatment ﬁelds.
Measures
Three primary predeﬁned outcomes of interest were
measured: (1) breast pain, (2) bother (related to itching,
stinging/burning, swelling, or hurting of the treated breast),
and (3) fatigue, deﬁned using the maximum value recorded
on any on-treatment weekly evaluation or on the end-oftreatment evaluation. Speciﬁcally, breast pain was
assessed using an approved modiﬁcation of the Brief Pain
Inventory12 that asks patients to rate their pain during the
last 24 hours at its worst, least, average, and “right now.”
Breast pain was considered moderate or severe when the
score on any one of those four items was $ 4 on the 10point scale.
Bother was measured using a modiﬁed scaled measure
adapted from the Skindex13 to include four symptoms of
interest (itching of the skin of the treated breast, burning or
stinging of the skin of the treated breast, swelling of the
treated breast, and hurting of the treated breast). Patients
were asked, “During the past week, how often have you
been bothered by…” for each symptom, with response
options of “never,” “rarely,” “sometimes,” “often,” or “all
the time.” Bother was considered frequent when the score
was “often” or “all the time” for any of the four subitems.
Fatigue was measured as in prior work2 with a single item
asking, “How often did you feel signiﬁcant fatigue?” and
was considered severe when rated as present “always” or
“most of the time” (rather than “sometimes,” “rarely,” or
“never”) over the past 4 weeks.
The patient characteristics analyzed included age (grouped
as , 50 years, 50-59 years, 60-69 years, or $ 70 years),
body mass index (BMI; grouped as , 18.5, 18.5 to , 25,
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25 to , 30, 30 to , 35, 35 to , 40, and $ 40), race
(deﬁned by self-report where available and otherwise by
clinician report, and grouped as White, Black, Asian, or
other, with the “other” category including categories of
American Indian/Alaska Native, Native Hawaiian or other
Paciﬁc Islander, Arab/Middle Eastern, or other),14 hypertension (yes or no), diabetes (yes or no), smoking status
(never, former, or current smoker), and chemotherapy
receipt (yes or no). Physical measures of body habitus
included from treatment planning scans were separation
distance from medial and lateral tangential beam entry
(continuously measured in centimeters) and breast volume
(continuously measured in cubic centimeters). Radiation
treatment technique characteristics that were included
were the use of a supraclavicular ﬁeld (with or without
additional regional ﬁelds) for radiotherapy (yes/no), fractionation (conventional fractionation v hypofractionation,
deﬁned as using a dose per fraction of 2.5 Gy or larger), and
use of boost (yes/no).
Analytic Approach
We ﬁrst described the outcomes of interest separately for
patients treated with conventional fractionation and those
treated with hypofractionation, given prior work suggesting
that these two groups had substantially different rates of
acute toxicity. Multilevel multivariable logistic regression
models separately identiﬁed the patient-level individual and
treatment characteristics associated with (1) breast pain,
(2) a bother scale (related to itching, stinging/burning,
swelling, or hurting of the treated breast), and (3) fatigue.
Patients were clustered within institution, with institution
associated as a random effect and whether the institution
teaches residents/medical students as the sole institutionlevel covariable. Given that the use of a supraclavicular ﬁeld
was almost exclusive to patients receiving conventional
fractionation, we constructed multivariable models of each
of the three outcomes separately for conventionally fractionated cases and hypofractionated cases after excluding
15 hypofractionated cases in which a supraclavicular ﬁeld
was used. P values # 5% were considered signiﬁcant, and
all analyses were conducted using the SAS System, version
9.4 (Cary, NC).
RESULTS
The characteristics of the study sample are reported for
4,268 conventionally fractionated and 4,443 hypofractionated cases in Table 1. Of patients receiving hypofractionation, 82.5% were White and 14.3% were Black; of
patients receiving conventional fractionation, 77.0% were
White and 19.1% were Black. Chemotherapy was known to
have been received by 15.9% of those receiving hypofractionation and 44.3% of those receiving conventional
fractionation.
Table 2 lists the frequencies of the three main outcomes
(and breakdown of the bother subitems) by fractionation.

Moderate or severe breast pain was reported by 3,233
(37.1%): 1,282 (28.9%) of those receiving hypofractionation and 1,951 (45.7%) of those receiving conventional
fractionation. Frequent bother from at least one breast
symptom was reported by 4,424 (50.8%): 1,833 (41.3%)
after hypofractionation and 2,591 (60.7%) after conventional fractionation. Severe fatigue was reported by 2,008
(23.1%): 843 (19.0%) after hypofractionation and 1,165
(27.3%) after conventional fractionation.
Figure 1 presents in its three panels the results of the
multivariable models of the three outcomes of interest
among patients receiving hypofractionated radiotherapy;
detailed model results are presented in Appendix Table A1
(online only). Patient-level factors independently and signiﬁcantly associated with moderate or severe breast pain
were younger age (P , .001), higher BMI (P , .001), Black
(P , .001) or other race (P 5 .002), former or current
smoking status (P , .001), and larger breast volume
(P 5 .002). Lack of receipt of chemotherapy (P 5 .004) and
receipt of boost treatment (P , .001) also predicted breast
pain. Treatment at a teaching center (P 5 .009) predicted
less breast pain. Factors independently and signiﬁcantly
associated with frequent bother from breast symptoms
were younger age (P , .001), higher BMI (P , .001), Black
race (P 5 .002), former or current smoking status
(P , .001), breast volume (P , .001), and separation
distance (P 5 .04). Lack of receipt of chemotherapy
(P , .001) and receipt of boost treatment (P , .001) also
predicted bother from breast symptoms. Factors independently and signiﬁcantly associated with severe fatigue were younger age (P , .001), higher BMI (P , .001),
Asian race (P 5 .004), and former or current smoking status
(P , .001). Treatment and dosimetric parameters were
not independently associated with fatigue among patients
treated with hypofractionation.
Figure 2 presents in its three panels the results of the
multivariable models of the three outcomes of interest
among patients receiving conventionally fractionated radiotherapy detailed model results are presented in
Appendix Table A2 (online only). Factors independently
and signiﬁcantly associated with moderate or severe breast
pain were younger age (P , .001), higher BMI (P 5 .003),
Black (P , .001) or other race (P 5 .002), diabetes
(P 5 .001), current or former smoking status (P , .001),
and larger breast volume (P , .001). Factors independently and signiﬁcantly associated with frequent
bother from breast symptoms were younger age (P , .001),
Black (P 5 .003) or other race (P 5 .004), hypertension (P , .001), diabetes (P , .001), current or former
smoking status (P , .001), breast volume (P , .001), and
separation distance (P 5 .01). Lack of receipt of chemotherapy (P 5 .007) and use of a supraclavicular ﬁeld
(P 5 .006) but not boost also predicted bother from breast
symptoms among patients receiving conventional fractionation. Factors independently and signiﬁcantly
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TABLE 1. Sample Description: Stratiﬁed by Fractionation Scheme
Variable/Level

Total

Hypofractionation

Conventional Fractionation

, 50

1,420 (16.30)

443 (9.97)

50-59

2,522 (28.95)

1,181 (26.58)

1,341 (31.42)

60-69

2,937 (33.72)

1,622 (36.51)

1,315 (30.81)

$ 70

1,832 (21.03)

1,197 (26.94)

635 (14.88)

Age group, years
977 (22.89)

BMI category, kg/m2
Underweight, , 18.5

147 (1.69)

Normal, 18.5 to , 25

1,984 (22.78)

63 (1.42)

84 (1.97)

1,043 (23.48)

941 (22.05)

Overweight, 25 to , 30

2,660 (30.54)

1,486 (33.45)

1,174 (27.51)

Obesity I, 30 to , 35

1,991 (22.86)

1,019 (22.93)

972 (22.77)

Obesity II, 35 to , 40

1,086 (12.47)

494 (11.12)

592 (13.87)

843 (9.68)

338 (7.61)

505 (11.83)

Obesity III, . 40

Breast volume, mL, continuous, mean 1,154.1 (699.31) [0.00-18,224.00] 1,074.5 (624.67) [0.00-14,338.90] 1,230.9 (756.55) [1.20-18,224.00]
(SD) [range]
Separation distance, cm, continuous,
mean (SD) [range]

22.73 (3.90) [10.00-42.00]

22.29 (3.70) [10.00-42.00]

23.19 (4.04) [10.00-40.83]

White

6,952 (79.81)

3,667 (82.53)

3,285 (76.97)

Black

1,452 (16.67)

635 (14.29)

817 (19.14)

Asian

137 (1.57)

57 (1.28)

80 (1.87)

Other

170 (1.95)

84 (1.89)

86 (2.01)

Race

Hypertension
No

4,706 (54.02)

2,350 (52.89)

2,356 (55.20)

Yes

4,005 (45.98)

2,093 (47.11)

1,912 (44.80)

No

7,393 (84.87)

3,794 (85.39)

3,599 (84.33)

Yes

1,318 (15.13)

649 (14.61)

669 (15.67)

Never smoker

5,052 (58.00)

2,586 (58.20)

2,466 (57.78)

Former smoker

2,724 (31.27)

1,422 (32.01)

1,302 (30.51)

Current smoker

935 (10.73)

435 (9.79)

500 (11.72)

80 (0.92)

45 (1.01)

35 (0.82)

Diabetes

Smoking status

Chemotherapy
Not reported
No

6,038 (69.31)

3,694 (83.14)

2,344 (54.92)

Yes

2,593 (29.77)

704 (15.85)

1,889 (44.26)

No

1,456 (16.71)

1,215 (27.35)

241 (5.65)

Yes

7,255 (83.29)

3,228 (72.65)

4,027 (94.35)

No

7,767 (89.16)

4,428 (99.66)

3,339 (78.23)

Yes

944 (10.84)

Boost

Supraclavicular ﬁeld
15 (0.34)

929 (21.77)

Institution teaching status
No

5,523 (63.40)

2,851 (64.17)

2,672 (62.61)

Yes

3,188 (36.60)

1,592 (35.83)

1,596 (37.39)

NOTE. Data are presented as No. (%) unless indicated otherwise.
Abbreviations: BMI, body mass index; SD, standard deviation.
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TABLE 2. Distribution of Patient-Reported Breast Pain, Bother, and Fatigue
Variable/Level

Total

Hypofractionation

Conventional Fractionation

3.13 (2.70) [0.00-10.00]

2.56 (2.45) [0.00-10.00]

3.71 (2.83) [0.00-10.00]

Pain rating maximum
Continuous, 0-10, mean (SD) [range]
Pain rating maximum level
None

1,516 (17.40)

990 (22.28)

526 (12.32)

Mild

3,962 (45.48)

2,171 (48.86)

1,791 (41.96)

Moderate

1,952 (22.41)

878 (19.76)

1,074 (25.16)

Severe

1,281 (14.71)

404 (9.09)

877 (20.55)

Frequent bother with itching
Missing

6 (0.07)

6 (0.14)

0 (0.00)

No

5,930 (68.07)

3,369 (75.83)

2,561 (60.00)

Yes

2,775 (31.86)

1,068 (24.04)

1,707 (40.00)

No

6,111 (70.15)

3,579 (80.55)

2,532 (59.33)

Yes

2,600 (29.85)

864 (19.45)

1,736 (40.67)

No

6,236 (71.59)

3,529 (79.43)

2,707 (63.43)

Yes

2,475 (28.41)

914 (20.57)

1,561 (36.57)

No

6,594 (75.70)

3,570 (80.35)

3,024 (70.85)

Yes

2,117 (24.30)

873 (19.65)

1,244 (29.15)

No

4,287 (49.21)

2,610 (58.74)

1,677 (39.29)

Yes

4,424 (50.79)

1,833 (41.26)

2,591 (60.71)

Frequent bother with stinging

Frequent bother with hurting

Frequent bother with swelling

Frequent bother from any breast symptom

Severe fatigue
Missing

750 (8.61)

393 (8.85)

357 (8.36)

No

5,953 (68.34)

3,207 (72.18)

2,746 (64.34)

Yes

2,008 (23.05)

843 (18.97)

1,165 (27.30)

NOTE. Data are presented as No. (%) unless indicated otherwise.
Abbreviation: SD, standard deviation.

associated with severe fatigue were younger age
(P , .001), higher BMI (P 5 .02), diabetes (P 5 .003),
former smoking status (P 5 .006), and separation distance
(P 5 .011). Treatment and dosimetric parameters were
not signiﬁcantly independently associated with fatigue
among patients treated with conventional fractionation.
Figure 3 presents the frequencies of the three main
outcomes by race for conventional and hypofractionated
cases, respectively.
DISCUSSION
This large multicenter study quantiﬁes patient-reported
experiences of pain, bother from breast symptoms, and
fatigue within 7 days of completing modern whole-breast
radiotherapy for breast cancer. This information is critically
important to inform patients who desire realistic information
about the likelihood of acute treatment-related toxicity in
their own individual circumstances. Several important

insights about patient and treatment factors associated with
toxicity emerged. Not only did outcomes differ by radiotherapy approach, including dose fractionation, boost
treatment, and regional nodal irradiation, but acute toxicity
also varied by body habitus, age, race, smoking behavior,
and comorbidities, with most factors consistent regardless
of which fractionation schedule was used.
Radiotherapy approaches that were associated with higher
acute toxicity included conventional fractionation, boost
radiotherapy among those receiving hypofractionation, and
regional nodal irradiation among those receiving conventional fractionation. The substantial differences observed
according to fractionation approach are consistent with the
ﬁndings of smaller prior reports and provide additional
support for efforts to ensure that all women for whom evidence exists to support the use of moderate hypofractionation are provided this option for treatment.14,15 The
observation that toxicity was higher in patients who received
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A

Odds Ratio and 95% CI
Age group, years: < 50
50-59
60-69 (referent)
≥ 70
BMI category (kg/m2): Underweight (< 18.5)
Normal (18.5 to < 25)
Overweight (25 to < 30) (referent)
Obesity I (30 to < 35)
Obesity II (35 to < 40)
Obesity II (> 40)
Race: White (referent)
Black
Asian
Other
Hypertension: Yes v No
Diabetes: Yes v No
Smoking status: Never smoker (referent)
Current smoker
Former smoker
Chemotherapy: Yes v No
Boost: Yes v No
Separation distance (1 cm)
Breast volume (100 mL)
Center: Academic v Community
0.1

1

OR

LCL

UCL

2.07
1.43
1
0.68
0.84
0.86
1
1.27
1.64
1.62
1
1.87
1.34
1.68
0.95
1.16
1
1.32
1.73
0.73
1.41
0.99
1.03
0.74

1.6
1.23

2.68
1.66

0.58
0.47
0.7

0.8
1.5
1.06

1.06
1.27
1.13

1.52
2.11
2.32

1.57
0.74
1.22
0.83
0.95

2.23
2.42
2.32
1.1
1.42

1.16
1.37
0.59
1.24
0.96
1.01
0.59

1.5
2.19
0.9
1.6
1.02
1.05
0.93

10

Favors less toxicity Favors more toxicity

B

Odds Ratio and 95% CI
Age group, years: < 50
50-59
60-69 (referent)
≥ 70
2
BMI category (kg/m ): Underweight (< 18.5)
Normal (18.5 to < 25)
Overweight (25 to < 30) (referent)
Obesity I (30 to < 35)
Obesity II (35 to < 40)
Obesity II (> 40)
Race: White (referent)
Black
Asian
Other
Hypertension: Yes v No
Diabetes: Yes v No
Smoking status: Never smoker (referent)
Current smoker
Former smoker
Chemotherapy: Yes v No
Boost: Yes v No
Separation distance (1 cm)
Breast volume (100 mL)
Center: Academic v Community
0.1

1

OR

LCL

UCL

2.55
1.66
1
0.7
1.32
0.89
1
0.9
1.34
1.35
1
1.33
0.84
1.18
0.85
0.9
1
1.1
1.63
0.69
1.75
0.97
1.04
0.84

2.16
1.47

3
1.87

0.6
0.67
0.74

0.82
2.61
1.07

0.75
1.01
0.99

1.08
1.78
1.84

1.11
0.49
0.73
0.71
0.72

1.61
1.41
1.9
1.01
1.12

1.02
1.33
0.62
1.54
0.95
1.02
0.68

1.2
1.98
0.76
1.99
1
1.06
1.04

OR

LCL

UCL

1.65
1.42
1
1.2
0.72
0.8
1
1.23
1.77
2.7
1
1.17
1.97
0.93
0.99
1.16
1
1.16
1.88
0.91
1.02
0.98
1
0.98

1.24
1.14

2.18
1.76

0.91
0.38
0.61

1.58
1.38
1.06

1.02
1.29
1.8

1.5
2.43
4.03

0.95
1.24
0.5
0.82
0.91

1.43
3.12
1.74
1.21
1.49

1.01
1.49
0.67
0.82
0.95
0.99
0.81

1.34
2.38
1.23
1.27
1
1.02
1.19

FIG 1. Results of three multivariable
models of patient-reported acute toxicity experiences among 4,428 patients treated with hypofractionated
whole-breast radiation therapy (and
without supraclavicular ﬁelds). (A)
Moderate or severe breast pain. (B)
Frequent bother from breast symptoms. (C) Severe fatigue. BMI, body
mass index; CL, conﬁdence limit; LCL,
Lower Conﬁdence Limit; OR, odds
ratio; UCL, Upper Conﬁdence Limit.
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FIG 2. Results of three multivariable
models of patient-reported acute
toxicity experiences among 4,268
patients treated with conventionally fractionated whole-breast radiation therapy (either with or without
supraclavicular ﬁelds). (A) Moderate
or severe breast pain. (B) Frequent
bother from breast symptoms. (C)
Severe fatigue. BMI, body mass index;
CL, conﬁdence limit; iSCV, Irradiated
Supraclavicular Lymph Nodes; LCL,
Lower Conﬁdence Limit; OR, odds
ratio; UCL, Upper Conﬁdence Limit.
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FIG 3. Frequency of patient-reported acute toxicity after breast radiotherapy, by fractionation and race.

boost radiotherapy, but only among those receiving
hypofractionated whole-breast radiotherapy, is intriguing.
This may reﬂect a true causal impact of boost treatment in
increasing toxicity in that setting, although it is also possible
that the additional week of observation in patients receiving
boost dose drives the difference observed, if acute toxicity
tends to manifest primarily after 3 weeks, as is plausible
given the transit time of the basal layer of the epidermis.
Additional research, including evaluation of patient experiences soon after completion of radiotherapy, as is now
being collected on a standard basis by the MROQC, will be
important in developing a more deﬁnitive understanding of
this observation. For now, this observation suggests that
efforts to delineate which patients derive meaningful beneﬁt
from boost radiotherapy are important. Finally, the observation of increased bother from breast symptoms among
patients who received regional nodal irradiation (who in this
analytic data set were all treated with conventional fractionation) suggests that discussion of acute toxicity is relevant to include when guiding patients for whom the
indications for regional nodal irradiation are ambiguous. It
also heightens the need for enrollment in trials such as NRG
B-5116 and NCIC MA-39,17 which seek to identify patients
in whom regional nodal irradiation can safely be omitted,
either because of excellent response to neoadjuvant
therapy in the case of B-51 or because of inherently favorable biologic features in the case of MA-39.
Several patient characteristics also correlated with the
patient-reported acute toxicity outcomes measured here.
One risk factor was larger body habitus (as measured by

BMI and by dosimetric parameters of separation distance
and breast volume). The higher rates of bother from breast
symptoms and pain in these patients likely relate to skin
and soft tissue reactions that develop in these patients.
These reactions result from the physical properties of
megavoltage beams used for modern radiotherapy administration that make obtaining dose homogeneity more
challenging in larger patients, together with the “auto-bolus
effect,” which increases skin dose in skin folds, where there
may also be additional damage because of friction. The
association of larger habitus with fatigue is intriguing; research should investigate whether a greater volume of irradiated tissue leads to higher levels of inﬂammatory
cytokine release and helps identify targets for prevention
and management of treatment-related fatigue. These
ﬁndings should also motivate ongoing research to identify
best dosimetric practices and whether alternative techniques, including partial breast irradiation, which has recently been found to result in minimal if any differences in
disease control,18-20 may be particularly useful in this patient population. They also suggest the importance of exploring how to improve supportive care, perhaps by
including additional nursing visits beyond the routine onceper-week physician examinations standard in radiation
oncology practice, to address the substantial symptoms
these patients experience.
Other groups of patients who may beneﬁt from greater
supportive care as they undergo radiation after breastconserving surgery are those of a younger age and Black
race. Whether the increased rates of toxicity reported in
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these patient groups reﬂect inherent biologic or socially
constructed socioeconomic differences of the patients
themselves or differences in provider and/or patient behavior merits additional attention. There is some reason to
believe that biologic differences may explain some of the
differences observed according to race; prior studies have
suggested that the frequency of genes involved in inﬂammation, wound repair, and ﬁbrotic response to radiation vary by race, although these studies have focused
primarily on genes related to late toxicity.21,22 There is also
reason to fear that social differences may explain other
aspects of the differences observed, especially if patients
who are Black or younger have, for example, less secure
ﬁnances to acquire supportive medications and topical
therapies.
Differences in provider behavior may also play a role
in explaining the race-related differences observed
herein. A litany of worrisome studies have shown providers
to be less sensitive to the pain of Black patients and less
likely to prescribe pain medication to them.23-31 One recent
study revealed that “false beliefs about biological differences between blacks and whites (e.g., ‘black people’s skin
is thicker than white people’s skin’)”32(p 4296) were endorsed
not only by White laypersons but also by one half of
a sample of White medical students and residents.
Moreover, those who endorsed the false beliefs were found
to demonstrate racial bias in the accuracy of their pain
treatment recommendations.32 Additional research is
necessary to determine the extent to which differences
detected in the current study reﬂect differences in provider
beliefs and behaviors and how best to mitigate bias in care
delivery. In any case, this study substantially advances
the understanding of how race does indeed seem to relate
to the experience of acute toxicity of whole-breast radiotherapy, given that prior research has been limited to much
smaller cohorts yielding mixed ﬁndings.33,34 Of great importance, however, is that these ﬁndings should not be
taken as a reason to dissuade Blacks from receiving breast
conservation as an approach to breast cancer management; rather, they should motivate efforts to optimize
supportive care.
In addition, observations of higher toxicity among smokers
and those with the comorbidities of hypertension and diabetes also merit note. Whether these might be modiﬁable
by smoking cessation or by tighter medical management of
the underlying comorbidities are important questions for
additional research. Intensifying supportive management is
also important for these patient groups.
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Finally, the observation that pain among patients treated
with hypofractionation was lower when they received
treatment at a teaching facility merits additional investigation. Future research should seek to identify which
aspects of care, such as differences in treatment planning
or toxicity management, at the academic institutions in this
study might explain why patients treated in those settings
had less pain. In this way, best practices to minimize pain
could be generalized.
Although this study has the strengths of prospectively
collecting patient-reported outcomes from a large number
of individuals in a multicenter setting reﬂecting modern
real-world practice in the United States, it also has several
limitations. First, as in any observational study, associations
cannot be taken to imply causation. Unmeasured confounding factors may exist. Second, although a high proportion of all eligible patients treated during the study
period participated, selection effects may also have biased
our ﬁndings. Third, because virtually no patients received
regional nodal irradiation in combination with hypofractionation, we were unable to evaluate whether supraclavicular ﬁelds increase toxicity among patients treated
with hypofractionation. Fourth, all data in the current study
reﬂect patient self-report and may differ from physicianreported toxicity; although some consider patient-reported
outcomes to be the gold standard, some might consider
such data to be subjective.35 We nevertheless believe that
the patient’s perspective provides irreplaceable information
that other patients would value as a reference for what they
might expect to experience. Fifth, differences in pain or
fatigue among patient groups may have existed before
radiation. Finally, we lacked information on when symptoms subsided.
In this large observational study of patient-reported toxicities after whole-breast radiotherapy, substantial differences existed not only according to radiotherapy dose
fractionation but also according to a number of other patient
personal and treatment characteristics. Of particular concern, race-related differences in breast pain and bother
existed despite controlling for multiple other factors, including age, body habitus, comorbidities, and treatment
characteristics. Additional research is needed to understand
the factors that drive these and other differences detected in
the current study, to target those that are potentially modiﬁable. Intensiﬁcation of supportive care may also be appropriate for subgroups identiﬁed as being vulnerable to
greater toxicity. Clinical trials must recruit diverse patients to
ensure that they adequately capture toxicity experiences.
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APPENDIX
TABLE A1. Multilevel Multivariable Models Explaining Toxicities for the Hypofractionated Cases (After Excluding 15 Cases With Supraclavicular Fields), With
Patients Clustered Within Institution
Moderate to Severe Breast Pain
Frequent Bother
Severe Fatigue
Variable/Level

OR (95% CI)

Pa

OR (95% CI)

Pa

OR (95% CI)

Pa

Patient-level variable/level
, .001b

Age group, years

, .001b

, .001b

, 50

2.07 (1.60 to 2.68)

, .001

2.55 (2.16 to 3.00)

, .001

1.65 (1.24 to 2.18)

, .001

50-59

1.43 (1.23 to 1.66)

, .001

1.66 (1.47 to 1.87)

, .001

1.42 (1.14 to 1.76)

.002

60-69 (referent)

1

$ 70

0.68 (0.58 to 0.80)
2

1
, .001

0.70 (0.60 to 0.82)

, .001

b

.003

BMI category, kg/m

Underweight, , 18.5

1
, .001

1.20 (0.91 to 1.58)

.19
, .001b

b

0.84 (0.47 to 1.50)

.56

1.32 (0.67 to 2.61)

.42

0.72 (0.38 to 1.38)

.33

Normal, 18.5 to , 25

0.86 (0.70 to 1.06)

.16

0.89 (0.74 to 1.07)

.22

0.80 (0.61 to 1.06)

.12

Overweight, 25 to , 30
(referent)

1

Obesity I, 30 to , 35

1.27 (1.06 to 1.52)

.009

0.90 (0.75 to 1.08)

.25

1.23 (1.02 to 1.50)

Obesity II, 35 to , 40

1.64 (1.27 to 2.11)

, .001

1.34 (1.01 to 1.78)

.04

1.77 (1.29 to 2.43)

, .001

Obesity III, . 40

1.62 (1.13 to 2.32)

.009

1.35 (0.99 to 1.84)

.06

2.70 (1.80 to 4.03)

, .001

1

, .001b

Race

1

.002b
1

.03

.004b

White (referent)

1

Black

1.87 (1.57 to 2.23)

, .001

Asian

1.34 (0.74 to 2.42)

.33

0.84 (0.49 to 1.41)

.50

1.97 (1.24 to 3.12)

.004

Other

1.68 (1.22 to 2.32)

.002

1.18 (0.73 to 1.90)

.50

0.93 (0.50 to 1.74)

.82

0.95 (0.83 to 1.10)

.53

0.85 (0.71 to 1.01)

.06

0.99 (0.82 to 1.21)

.95

.14

0.90 (0.72 to 1.12)

.35

1.16 (0.91 to 1.49)

1.33 (1.11 to 1.61)

1
.003

1.17 (0.95 to 1.43)

.14

Hypertension
Yes v No
Diabetes
Yes v No

1.16 (0.95 to 1.42)

, .001b

, .001b

Smoking status

1

.23
, .001b

Never smoker (referent)

1

Former smoker

1.32 (1.16 to 1.50)

, .001

1.10 (1.02 to 1.20)

.02

1
1.16 (1.01 to 1.34)

Current smoker

1.73 (1.37 to 2.19)

, .001

1.63 (1.33 to 1.98)

# .001

1.88 (1.49 to 2.38)

0.73 (0.59 to 0.90)

.004

0.69 (0.62 to 0.76)

, .001

0.91 (0.67 to 1.23)

.53

1.41 (1.24 to 1.60)

# .001

1.75 (1.54 to 1.99)

, .001

1.02 (0.82 to 1.27)

.85

Separation distance, centered at
22 cm, continuous

0.99 (0.96 to 1.02)

.47

0.97 (0.95 to 1.00)

.03

0.98 (0.95 to 1.00)

.10

Breast volume per 100 mL,
centered at 1,150 mL,
continuous

1.03 (1.01 to 1.05)

.002

1.04 (1.02 to 1.06)

, .001

1.00 (0.99 to 1.02)

.39

0.74 (0.59 to 0.93)

.009

0.84 (0.68 to 1.04)

.11

0.98 (0.81 to 1.19)

.85

.04
, .001

Chemotherapy
Yes v No
Boost
Yes v No

Institution-level variable/level
Teaching institution
Yes v No

Abbreviations: BMI, body mass index; OR, odds ratio.
a
For factors with more than two levels, the overall, group P value is reported together with pairwise P values for each level of the factor compared with the
reference level.
b
Group P value.
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TABLE A2. Multilevel Multivariable Models Explaining Toxicities for the Conventionally Fractionated Cases, With Patients Clustered Within Institution
Moderate to Severe Breast Pain
Variable/Level

OR (95% CI)

P

Frequent Bother

a

OR (95% CI)

Severe Fatigue
P

a

OR (95% CI)

Pa

Patient-level variables/level
, .001b

Age group, years

, .001b

, .001b

, 50

2.02 (1.72 to 2.38)

, .001

2.18 (1.85 to 2.57)

, .001

1.51 (1.19 to 1.92)

, .001

50-59

1.63 (1.44 to 1.84)

, .001

1.71 (1.45 to 2.01)

, .001

1.35 (1.12 to 1.62)

.002

60-69 (referent)

1

$ 70

0.89 (0.77 to 1.03)

BMI category, kg/m2

1
.12

0.72 (0.60 to 0.88)

.003b

1
.001

0.86 (0.68 to 1.08)

.85b

.19
.017b

Underweight, , 18.5

0.93 (0.60 to 1.44)

.75

1.16 (0.77 to 1.75)

.46

1.19 (0.82 to 1.72)

.36

Normal, 18.5 to , 25

0.83 (0.66 to 1.05)

.11

1.03 (0.80 to 1.33)

.82

0.79 (0.60 to 1.05)

.11

Overweight, 25 to , 30 (referent)

1

Obesity I, 30 to , 35

1.14 (0.92 to 1.40)

.23

1.00 (0.83 to 1.22)

.98

1.21 (0.94 to 1.55)

.14

Obesity II, 35 to , 40

1.10 (0.88 to 1.38)

.40

0.91 (0.73 to 1.13)

.40

1.04 (0.79 to 1.37)

.78

Obesity III, . 40

1.51 (1.12 to 2.03)

.006

0.99 (0.69 to 1.42)

.95

1.00 (0.70 to 1.42)

.99

1

, .001b

, .001b

Race
White (referent)

1

Black

2.04 (1.69 to 2.47)

Asian

1.44 (0.78 to 2.66)

Other

2.16 (1.34 to 3.50)

0.89 (0.78 to 1.03)

1

1
, .001

.95b
1

1.35 (1.11 to 1.65)

.003

0.92 (0.65 to 1.30)

.62

.24

0.75 (0.46 to 1.21)

.24

0.98 (0.61 to 1.57)

.95

.002

1.88 (1.23 to 2.87)

.004

1.04 (0.65 to 1.66)

.88

.11

0.77 (0.69 to 0.87)

, .001

1.14 (0.96 to 1.34)

.13

.001

1.36 (1.14 to 1.64)

, .001

1.35 (1.10 to 1.65)

.003

Hypertension
Yes v No
Diabetes
Yes v No

1.29 (1.11 to 1.50)

, .001b

, .001b

Smoking status
Never smoker (referent)

1

Former smoker

1.19 (1.03 to 1.38)

Current smoker

1.58 (1.30 to 1.91)

1
.02
, .001

.006b
1

1.28 (1.14 to 1.44)

, .001

1.12 (0.93 to 1.36)

.23

1.65 (1.32 to 2.07)

, .001

1.45 (1.16 to 1.83)

.001

Chemotherapy
Yes v No

0.85 (0.72 to 1.02)

.08

0.78 (0.65 to 0.93)

.007

0.86 (0.74 to 1.00)

.05

1.09 (0.83 to 1.43)

.53

1.08 (0.83 to 1.42)

.56

0.82 (0.61 to 1.09)

.17

Separation distance, centered
at 22 cm, continuous

1.02 (0.98 to 1.06)

.35

1.03 (1.01 to 1.06)

.01

1.04 (1.01 to 1.07)

.01

Breast volume per 100 mL,
centered at 1,150 mL, continuous

1.03 (1.02 to 1.04)

1.04 (1.02 to 1.06)

, .001

1.00 (0.99 to 1.01)

.66

Boost
Yes v No

, .001

Supraclavicular ﬁeld
Yes v No

1.06 (0.89 to 1.27)

.52

1.17 (1.04 to 1.30)

.006

0.84 (0.70 to 1.01)

.06

0.91 (0.65 to 1.28)

.60

0.97 (0.72 to 1.31)

.86

1.02 (0.87 to 1.20)

.82

Institution-level variable/level
Teaching institution
Yes v No

Abbreviations: BMI, body mass index; OR, odds ratio.
a
For factors with more than two levels, the overall, group P value is reported together with pairwise P values for each level of the factor compared with the
reference level.
b
Group P value.
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